
|Videos|April 27, 2017
Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer
Author(s)Johanna C. Bendell, MD
Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).
Advertisement
Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
The OncFive: Top Oncology Articles for the Week of 5/31
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5




































































